UniQure's therapy slows Huntington's disease progression in trial; Shares more than triple
UniQure's experimental gene therapy for Huntington's disease slowed progression of the brain disorder by 75% in an early-to-mid stage study, the company said.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
UniQure
since
auto-detected in 2 stories
73 days ago
Stocks making the biggest moves midday: Alibaba, Lithium Americas, Freeport-McMoRan, UniQure and more
These are the stocks posting the largest moves in midday trading.
page 1 of 1